{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=6", "query": { "intervention": "Dose level 3", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 17818, "total_pages": 1782, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T02:18:31.955Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07822399", "title": "A Study of MGC030 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Cancer", "GastroEsophageal Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer (GC)", "Pancreatic Cancer" ], "interventions": [ { "name": "MGC030", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2026-10-07", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07822399" }, { "nct_id": "NCT02232893", "title": "Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postoperative Ileus" ], "interventions": [ { "name": "Daikenchuto (TU-100)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tsumura USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2014-09", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2020-06-19", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 13, "location_summary": "Los Angeles, California • Aurora, Colorado • Weston, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Weston", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02232893" }, { "nct_id": "NCT00513604", "title": "Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Malignant Melanoma", "Melanoma, Experimental", "Experimental Melanomas" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2007-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2013-06-03", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513604" }, { "nct_id": "NCT03646604", "title": "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Upadacitinib (ABT-494)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "2 Years to 12 Years" }, "enrollment_count": 35, "start_date": "2019-01-31", "completion_date": "2024-08-29", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 15, "location_summary": "Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646604" }, { "nct_id": "NCT05735184", "title": "A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Mixed Lineage Leukemia Gene Mutation", "Refractory AML", "AML With Mutated NPM1", "Acute Myeloid Leukemia Recurrent", "Acute Myeloid Leukemia, in Relapse", "NPM1 Mutation", "KMT2Ar", "Myeloid Sarcoma", "Nucleophosmin 1-mutated Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Quizartinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-07-18", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 44, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05735184" }, { "nct_id": "NCT00938652", "title": "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "Iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 519, "start_date": "2009-07", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-09-19", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 102, "location_summary": "Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00938652" }, { "nct_id": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Hepatocellular Cancer", "Mesothelioma", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Nasopharyngeal Cancer", "Kidney Cancer", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC), Non-squamous" ], "interventions": [ { "name": "TAK-500", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-04-14", "completion_date": "2025-01-06", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070247" }, { "nct_id": "NCT02743871", "title": "Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Chronic Rhinosinusitis With Nasal Polyps", "Atopic Dermatitis" ], "interventions": [ { "name": "PF-06817024", "type": "BIOLOGICAL" }, { "name": "Placebo for PF-06817024", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 97, "start_date": "2016-04-27", "completion_date": "2021-03-09", "has_results": true, "last_update_posted_date": "2022-05-19", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 20, "location_summary": "Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Shelton", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02743871" }, { "nct_id": "NCT05208944", "title": "THIO Sequenced With Cemiplimab in Advanced NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "6-Thio-2'-Deoxyguanosine", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Maia Biotechnology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2022-06-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Florham Park, New Jersey", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Florham Park", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05208944" }, { "nct_id": "NCT03250832", "title": "Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-033", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-08-08", "completion_date": "2023-02-13", "has_results": true, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-11-12T02:18:31.955Z", "location_count": 11, "location_summary": "Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250832" } ] }